Introduction
Inflammatory bowel diseases (IBD), including Crohn’s disease and Ulcerative colitis, are chronic inflammatory conditions of the gastrointestinal tract with a rising global incidence. Although their exact cause remains unclear, IBD is widely understood to result from disrupted interactions between the gut microbiota and the mucosal immune system, influenced by genetic predisposition, environmental factors, diet, and antibiotic exposure.
Recent research highlights the importance of microbial metabolites in maintaining intestinal homeostasis. Among these, succinate has emerged as a key signaling molecule. Traditionally viewed as a metabolic intermediate, succinate is now recognized as an active mediator that accumulates during inflammation and metabolic stress, contributing to immune regulation and disease progression.
Sources of Succinate in the Intestine
Host-Derived Succinate
Succinate is a central intermediate of the Tricarboxylic acid cycle, a critical pathway for cellular energy production in mitochondria. It is generated during the conversion of succinyl-CoA and further oxidized into fumarate by succinate dehydrogenase, linking the TCA cycle to the electron transport chain.
Under hypoxic conditions or mitochondrial dysfunction, succinate accumulates due to impaired oxidation. This excess can exit the mitochondria and enter the cytosol, where it serves as a marker of metabolic stress. During inflammation, succinate may also be released into the extracellular environment, potentially through cell damage or necrosis.
Microbe-Derived Succinate
In the gut lumen, succinate is largely produced by anaerobic bacterial fermentation. Members of the Bacteroidetes are major contributors to succinate production. Under normal conditions, succinate levels remain low because it is rapidly converted into short-chain fatty acids (SCFAs), particularly propionate.
However, disruptions in microbial balance such as antibiotic use, dietary shifts, or dysbiosis can impair this conversion, leading to succinate accumulation. Elevated levels have been observed in conditions like antibiotic-associated diarrhea and IBD, indicating altered microbial metabolism.
Succinate Accumulation and IBD
Clinical and experimental studies consistently show increased succinate levels in intestinal tissues and feces of IBD patients. Similar findings are reported in animal models of colitis, where succinate concentration correlates with disease severity.
This accumulation may result from both host-derived metabolic stress and microbial dysbiosis. Reduced populations of succinate-consuming bacteria and increased abundance of succinate-producing species contribute to this imbalance. These findings suggest that succinate is not just a byproduct but a metabolic signature of intestinal inflammation.
Impact of Succinate on Intestinal Immune Responses
Intracellular Effects: Hypoxia and HIF-1α
Inside cells, succinate plays a regulatory role in response to low oxygen levels by stabilizing HIF-1α. This transcription factor controls genes involved in adaptation to hypoxia, including those supporting epithelial barrier integrity and reducing cell death.
However, excessive succinate can induce “pseudohypoxia,” activating HIF-1α even in normal oxygen conditions. This may enhance inflammatory signaling, including the production of cytokines such as IL-1β, thereby amplifying immune responses.
Extracellular Signaling: SUCNR1 Activation
Extracellular succinate exerts its effects through the receptor SUCNR1, a G protein-coupled receptor expressed in immune and epithelial cells. Activation of this receptor triggers signaling pathways that regulate inflammation, including MAPK and calcium dependent pathways.
Succinate-SUCNR1 signaling promotes immune cell recruitment, cytokine production, and macrophage activation. It also influences immune cell polarization, favoring pro-inflammatory responses in certain contexts. In experimental models, deficiency of SUCNR1 reduces inflammation and tissue damage, highlighting its role in disease progression.
Interestingly, succinate signaling can also activate protective immune pathways. In intestinal epithelial tuft cells, SUCNR1 stimulation induces type 2 immune responses that support barrier function and tissue repair, demonstrating the dual nature of succinate signaling.
Succinate and the Gut Microbiome
Pathogen Exploitation
Elevated succinate levels can be exploited by pathogenic bacteria. Organisms such as Escherichia coli, Clostridium difficile, and Salmonella utilize succinate as a nutrient source or signal to activate virulence genes. This enhances their growth and pathogenicity, contributing to disease severity.
Microbial Balance and Cross-Feeding
Despite its pathogenic potential, succinate also plays a beneficial role in microbial ecology. It serves as an intermediate in cross-feeding interactions, supporting the production of beneficial SCFAs like butyrate and propionate. These metabolites have well-established anti-inflammatory effects and contribute to gut health.
Thus, the impact of succinate depends on the overall microbial composition and metabolic balance within the gut ecosystem.
Clinical Implications and Therapeutic Perspectives
The dual role of succinate in inflammation and microbial dynamics makes it a promising target for therapeutic intervention. Strategies may include:
- Modulating gut microbiota to restore succinate balance
- Targeting SUCNR1 signaling pathways
- Enhancing SCFA production to counteract pro-inflammatory effects
Understanding the context-dependent effects of succinate is essential for developing effective treatments for IBD and related disorders.
Conclusion
Succinate is a key metabolic and signaling molecule at the intersection of host metabolism, immune regulation, and microbial activity. Its accumulation in IBD reflects both metabolic stress and microbial imbalance. While it can activate protective responses, excessive or dysregulated succinate signaling contributes to inflammation and disease progression.
Future research should focus on clarifying these complex interactions and leveraging them to design targeted therapies that restore intestinal homeostasis and improve patient outcomes.